UChicago researchers have developed a new blood test that uses RNA modifications to detect early-stage colorectal cancer with ...

While the liquid biopsy technology continues to evolve for lung cancer management, researchers are working toward further ...

NeoGenomics launched the NEO PanTracer™ LBx, a blood-based comprehensive genomic profiling test, expanding the company’s ...

A groundbreaking study reveals that Guardant Reveal's liquid biopsy detects immunotherapy responses earlier, enhancing ...

Exosomes Market DataM Intelligence forecasts robust exosome market growth fueled by AI-driven diagnostics, automated manufacturing, and str ...

Liquid biopsy is a new technique that makes it easier to identify and monitor lung cancer without surgery. In India, this ...

Guardant Health raised its FY2025 sales guidance from $880.00 million-$890.00 million to $915.00 million-$925.00 million.

A research team has developed a technology that distinguishes lung cancer gene mutations solely by measuring the "stiffness" ...

A study from the University of Chicago introduces an RNA-based liquid biopsy that detects early-stage colorectal cancer with 95% accuracy. The test overcomes the limitations of DNA-based methods.

Urologic cancers, which include prostate, bladder, and kidney malignancies, pose significant global health challenges due to ...

DGIST research team led by Yoonhee Lee and Gyogwon Koo enhances lung cancer diagnostic accuracy by combining exosome physical ...